Medtronic-Sponsored Economic Analysis Supports CRT Devices As Cost-Effective
Executive Summary
New analysis from the Medtronic-sponsored REVERSE trial shows that patients with mild heart failure receiving CRT therapy had an ICER (incremental cost effectiveness ratio) of $8,840 per QALY, compared to those not receiving CRT.
You may also be interested in...
More Patients Should Receive Cardiac Resynchronization Therapy, Heart Groups Say
In revised practice guidelines released Sept. 10, the American Heart Association, the Heart Rhythm Society and the American College of Cardiology Foundation say new evidence shows that many patients with mild heart failure can benefit from cardiac resynchronization devices.
Boston Scientific Gains Expanded Indication For CRT-D Devices
Boston Scientific hopes its newfound ability to legally market its cardiac resynchronization therapy defibrillators for use in a broader heart failure population will help its efforts to regain lost market share in the sector
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
Preliminary results of Boston Scientific's MADIT-CRT study show a significant benefit for cardiac resynchronization therapy implants over conventional defibrillators for patients with mild heart failure; the data could support expanded labeling and increased market adoption for the premium-priced devices, industry watchers say